HROW vs PAHC vs IMVT vs INVA vs AMRX

For growth investors, Harrow Health, Inc.

(HROW) is the stronger pick with 36. 4% revenue growth year-over-year, versus 8. 0% for Amneal Pharmaceuticals, Inc. (AMRX). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Harrow Health, Inc. (HROW) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Amneal Pharmaceuticals, Inc. at 62. 4x. On forward P/E, Innoviva, Inc. is actually cheaper at 11. 9x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Innoviva, Inc. wins at 1. 15x versus Phibro Animal Health Corporation's 1. 90x — a reasonable growth-adjusted valuation.

Over the past 5 years, Harrow Health, Inc.

(HROW) delivered a total return of +378. 0%, compared to +62. 4% for Immunovant, Inc. (IMVT). Over 10 years, the gap is even starker: HROW returned +914. 3% versus AMRX's -54. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Harrow Health, Inc. 's 2. 13β — meaning HROW is approximately 1587% more volatile than INVA relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 5% for Harrow Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Harrow Health, Inc.

(HROW) is pulling ahead at 36. 4% versus 8. 0% for Amneal Pharmaceuticals, Inc. (AMRX). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -45. 2% for Immunovant, Inc.. Over a 3-year CAGR, HROW leads at 45. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -1. 9% for Harrow Health, Inc. — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INVA leads at 38. 5% versus -0. 2% for AMRX. At the gross margin level — before operating expenses — HROW leads at 75. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Innoviva, Inc. (INVA) is the more undervalued stock at a PEG of 1. 15x versus Phibro Animal Health Corporation's 1. 90x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Innoviva, Inc. (INVA) trades at 11. 9x forward P/E versus 82. 9x for Harrow Health, Inc. — 70. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for HROW: 93. 8% to $75. 67.

In this comparison, PAHC (1.

1% yield) pays a dividend. HROW, IMVT, INVA, AMRX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Innoviva, Inc.

(INVA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 13)). Harrow Health, Inc. (HROW) carries a higher beta of 2. 13 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (INVA: +94. 9%, HROW: +914. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: HROW is a small-cap high-growth stock; PAHC is a small-cap high-growth stock; IMVT is a small-cap quality compounder stock; INVA is a small-cap high-growth stock; AMRX is a small-cap quality compounder stock. PAHC pays a dividend while HROW, IMVT, INVA, AMRX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.